Dynamic Technology Lab Private Ltd Acquires Shares of 4,300 Eagle Pharmaceuticals, Inc. (EGRX)

Dynamic Technology Lab Private Ltd acquired a new position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,300 shares of the specialty pharmaceutical company’s stock, valued at approximately $257,000.

Other large investors also recently bought and sold shares of the company. Argent Capital Management LLC purchased a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter worth $686,000. Russell Investments Group Ltd. increased its stake in shares of Eagle Pharmaceuticals by 7,357.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 46,084 shares of the specialty pharmaceutical company’s stock worth $3,634,000 after purchasing an additional 45,466 shares in the last quarter. Blair William & Co. IL increased its stake in shares of Eagle Pharmaceuticals by 7.2% in the 2nd quarter. Blair William & Co. IL now owns 79,035 shares of the specialty pharmaceutical company’s stock worth $6,235,000 after purchasing an additional 5,340 shares in the last quarter. Advisory Services Network LLC increased its stake in shares of Eagle Pharmaceuticals by 52.8% in the 2nd quarter. Advisory Services Network LLC now owns 12,225 shares of the specialty pharmaceutical company’s stock worth $964,000 after purchasing an additional 4,225 shares in the last quarter. Finally, U S Global Investors Inc. purchased a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter worth $1,097,000.

Shares of Eagle Pharmaceuticals, Inc. (NASDAQ EGRX) opened at $55.68 on Friday. Eagle Pharmaceuticals, Inc. has a 12 month low of $45.05 and a 12 month high of $97.15. The company has a quick ratio of 5.15, a current ratio of 5.30 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $876.35, a price-to-earnings ratio of 9.26 and a beta of 1.24.

Several equities research analysts have recently commented on the company. ValuEngine upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. BidaskClub upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, December 2nd. Mizuho reiterated a “sell” rating and issued a $37.00 price target on shares of Eagle Pharmaceuticals in a research note on Wednesday, November 8th. Royal Bank of Canada reiterated an “outperform” rating and issued a $75.00 price target (down previously from $81.00) on shares of Eagle Pharmaceuticals in a research note on Thursday, November 9th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $75.00 price target on shares of Eagle Pharmaceuticals in a research note on Friday, October 27th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. Eagle Pharmaceuticals currently has an average rating of “Hold” and an average target price of $62.33.

COPYRIGHT VIOLATION NOTICE: “Dynamic Technology Lab Private Ltd Acquires Shares of 4,300 Eagle Pharmaceuticals, Inc. (EGRX)” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://ledgergazette.com/2017/12/15/dynamic-technology-lab-private-ltd-invests-257000-in-eagle-pharmaceuticals-inc-egrx-stock.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply